COSM · Cosmos Health Inc.
Substantial doubt about the company's ability to continue as a going concern.
“These conditions raise substantial doubt about the Company's ability to continue as a going concern for a period of 12 months from the date of this filing.”View the 10-Q filed Aug 18, 2026
Price & Indicators
Up next
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted Gross Profit non-GAAP | $3,695,361 | Six Months Ended June 30, 2026 | — |
| Adjusted Net Income (Loss) per Share non-GAAP | -$0.12 | FY 2025 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Distribution — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
COSM
this stock
Cosmos Health Inc.
|
$22.61M | -54.9% | +19.9% | — | 3.8% |
|
MCK
Mckesson Corp
|
$103.82B | +8.9% | +3.1% | 23.9 | 2.1% |
|
COR
Cencora, Inc.
|
$61.45B | -4.7% | +9.3% | 23.9 | 2.4% |
|
CAH
Cardinal Health Inc
|
$54.55B | +14.1% | +14.2% | — | 2.7% |
|
HSIC
Henry Schein Inc
|
$9.98B | +18.4% | +5.9% | 26.1 | 6.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| COSM | +1.2% | +4.0% | -41.6% | +4.0% | -54.9% |
| SPY | +0.5% | +3.0% | +13.4% | +3.0% | +12.8% |
| vs SPY | +0.8% | +1.0% | -55.1% | +1.0% | -67.7% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.